Vascular Access, Infusion Monitoring, and Extravasation Prevention

Vascular Access, Infusion Monitoring, and Extravasation Prevention

Systemic therapy depends on safe vascular access. Device choice reduces delays, tissue injury, infection, and thrombosis. Selection weighs vesicant status, osmolarity, pH, infusion duration, vein quality, lymphedema risk, and patient preference. A vesicant causes tissue necrosis if it leaks; an irritant causes inflammation or pain without necrosis; a nonvesicant does neither.

Vesicant Examples and Access

Known DNA-binding vesicants include the anthracyclines (doxorubicin, daunorubicin) and non-DNA-binding vesicants include the vinca alkaloids (vincristine, vinblastine). Vesicants are preferentially given through central venous access (implanted port, tunneled catheter, or peripherally inserted central catheter [PICC]); when a peripheral route is used, choose a fresh, large forearm vein with the site visible, confirm blood return, and avoid the antecubital fossa, wrist, hand, and any area of flexion.

Suspected Extravasation Response

Extravasation is leakage of a vesicant into surrounding tissue. If suspected: stop the infusion immediately, leave the catheter in place, aspirate residual drug through the catheter, do not flush, and disconnect tubing. Then apply the drug-specific antidote and compress:

• Anthracyclines (e.g., doxorubicin): apply cold compresses to localize; give dexrazoxane IV in a different limb if ordered (within about 6 hours).
• Vinca alkaloids (e.g., vincristine, vinblastine): apply warm compresses to disperse; give hyaluronidase subcutaneously around the site.

Mark and photograph the area per policy, measure it, notify provider and pharmacy, document thoroughly, and arrange follow-up because tissue injury evolves over days. Applying the wrong temperature (cold to a vinca alkaloid, warm to an anthracycline) worsens injury.

Infusion Monitoring and Central-Line Complications

Monitor vital signs, line patency, pump settings, and symptoms, with heightened reaction readiness for first infusions, taxanes, platinums, monoclonal antibodies, and asparaginase. Emergency equipment must be available. For central lines, assess dressing integrity, blood return, and patient-reported changes. Fever with a central line during neutropenia demands prompt evaluation for central-line-associated bloodstream infection (CLABSI). New arm, neck, or facial swelling on the catheter side suggests catheter-related thrombosis. Teach patients to keep dressings dry, avoid pulling the line, and report fever or drainage.

Device Selection in Practice

The right device prevents downstream harm. Peripheral IV access suits short, nonvesicant, low-osmolarity infusions in a healthy, visible vein. Central access is preferred or required for vesicants, continuous infusions, poor peripheral veins, frequent draws, prolonged therapy, or vesicant chemotherapy. Each central device carries a distinct risk profile: implanted ports lower infection and body-image burden but require needle access through skin; tunneled catheters and PICCs offer immediate access but add daily maintenance and thrombosis risk.

The RN matches device to therapy and escalates when the planned drug does not fit the available access rather than forcing a vesicant through a marginal peripheral site.

Why Compress Direction Matters

The cold-versus-warm rule is a frequently tested distinction. For DNA-binding anthracycline vesicants, cold vasoconstricts and localizes the drug, limiting the area of necrosis, and dexrazoxane neutralizes the tissue injury. For non-DNA-binding vinca alkaloids, warm vasodilates and disperses the drug to dilute it, and hyaluronidase breaks down tissue barriers to spread and absorb the small leaked volume. Reversing these (warming an anthracycline or cooling a vinca alkaloid) worsens the lesion, so the nurse always consults the agent-specific protocol rather than applying a single generic response.

Injury can evolve over days to weeks, so photographic documentation, measurement, and scheduled follow-up are part of the standard.

A Common Safety Failure

A frequent error is assuming a quiet patient has no site symptoms. Many patients minimize discomfort because they traveled far or fear a delay. The RN should invite reporting in direct language, pain, burning, tightness, pressure, or wetness should be reported immediately, and should recheck the site after position changes, bathroom trips, and pump alarms. Early interruption of an infusion through uncertain access is always safer than finishing the dose and discovering necrosis later.

Distinguishing Infiltration, Extravasation, and Flare

Three look-alike events require different responses. Infiltration is leakage of a nonvesicant into tissue, causing swelling and coolness but not necrosis; the nurse stops, removes the catheter, and elevates. Extravasation is leakage of a vesicant and threatens tissue loss, demanding the stop-aspirate-antidote sequence with the catheter left in place.

A flare reaction (most classic with doxorubicin) is a transient local erythema, urticaria, or streaking along the vein, with blood return still intact and no pain or swelling; it is a local hypersensitivity, not extravasation, and usually resolves, though the nurse pauses and assesses to confirm patency before resuming. Mistaking a flare for extravasation triggers unnecessary intervention, while mistaking extravasation for a flare delays the antidote, so the distinguishing features, pain, swelling, and loss of blood return, must be assessed deliberately.

Monitoring High-Risk First Infusions

Reaction readiness scales with the agent. First infusions of monoclonal antibodies, taxanes, platinum agents, and asparaginase products carry elevated reaction risk, so the nurse confirms emergency medications and equipment are at hand, takes baseline vital signs, and stays at the bedside through the early minutes. The RN must be able to pause the infusion, maintain access with non-drug fluid, call for help, and support airway and circulation while awaiting provider direction, the same reflex used for any infusion reaction.